Fig. 2
DNA-PK inhibition enhances anticancer activity of OV M1. a Cells were incubated with increasing concentrations of NU7441 (0.5, 1, 2, 4, 8 μM) in the absence or presence of M1 virus (MOI = 1), and the differences in the AUC (fold) between two dose–response curves for each cell line were calculated according to the formula (AUCSingle – AUCCombined)/AUCCombined. b, c Relative cell viability in HCT-116 cells treated with vehicle, M1, DNA-PK inhibitors (NU7026: 8 μM or KU0060648: 100 nM, KU represents KU0060648), or a combination. n = 3. d, f, Western blot of the cells infected with siRNAs targeting DNA-PKcs. NC, negative control siRNA; 1, 2 and 3 represent three siRNAs targeting DNA-PKcs. e, g, Relative cell viability of tumour cells treated with siRNA targeting DNA-PKcs (48 h), followed by M1 virus infection (MOI = 1). NC, negative control siRNA. n = 3. Data shown as the mean ± SD in b, c, e, g. **P < 0.01; ***P < 0.001 by one-way ANOVA for b, c or two-tailed Student’s t-test for e, g
